Chemotherapy for Potentially Resectable Locally Advanced Esophagogastric

Updated 06/21/2024

Status Recruiting

Clinical Trial Summary

This is a non-interventional study to observe the safety and efficiency of chemotherapy for potentially resectable locally advanced esophagogastric junction

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Esophagogastric Junction Cancer

Clinical Trial Details

NCT number	NCT03211377
Study type	Observational
Source	Anyang Tumor Hospital
Contact	Li Baozhong
Phone	0372-2923314
Email	drlibaozhong@163.com
Status	Recruiting
Phase	N/A
Start date	March 29, 2017
Completion date	April 29, 2021

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT04752358` - ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)	Phase 2
	Recruiting	`NCT02988921` - MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy	N/A
	Completed	`NCT02979691` - Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01	Phase 2/Phase 3
	Completed	`NCT01248403` - A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy	Phase 3
	Not yet recruiting	`NCT06310473` - Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial	Phase 2
	Recruiting	`NCT04821778` - Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer	Phase 3
	Recruiting	`NCT05275062` - Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma	Early Phase 1
	Recruiting	`NCT05259696` - Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)	Phase 1/Phase 2
	Recruiting	`NCT03139487` - A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism	Phase 2
	Recruiting	`NCT04675138` - Development of a Clinical Decision Support System With Artificial Intelligence for Cancer Care
	Withdrawn	`NCT05245760` - ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer	Phase 2